227. Osler disease
49 clinical trials,   69 drugs   (DrugBank: 21 drugs),   23 drug target genes,   132 drug target pathways

Searched query = "Osler disease", "Hereditary hemorrhagic telangiectasia", "Osler-Weber-Rendu disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2011-004096-36-IT
(EUCTR)
11/10/201119/03/2012Efficacy of thalidomide in the treatment of heavy and frequent nose bleeding in patients affected by hereditary hemorrhagic telangiectasiaEfficacy of thalidomide in the treatment of severe recurrent epistaxis in hereditary hemorrhagic telangiectasia (HHT) Severe recurrent epistaxis in hereditary hemorrhagic telangiectasia
MedDRA version: 14.1;Level: LLT;Classification code 10038554;Term: Rendu-Osler-Weber syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Trade Name: THALIDOMIDE CELGENE*28CPS 50MG
INN or Proposed INN: THALIDOMIDE
OSPEDALE POLICLINICO S. MATTEONULLNot RecruitingFemale: yes
Male: yes
31Phase 2Italy